Integrated solutions encompassing equipment, reagents and information systems

「We will provide Sysmex's proprietary healthcare DX solutions by combining the extensive testing data accumulated from our customer base spanning more than 190 countries with AI analysis technologies. In addition to guiding appropriate medical care based on test results, we will promote operational efficiency through AI-based support for laboratory operations and pursue the creation of new value that contributes both to addressing healthcare challenges and to healthcare cost-effectiveness, including support for public health.」

「By combining extensive testing data from our customer base spanning more than 190 countries with proprietary AI analysis technologies, we will provide Sysmex's unique healthcare DX solutions.」

「This system automates the entire workflow for clinical FCM testing, from specimen pretreatment through to obtaining measurement results. This improves testing efficiency and standardization, reduces the workload of clinical laboratory technologists, and enables them to focus on analyzing and interpreting measurement results that require greater expertise.」

「We will continue efforts to renew next-generation core systems and digital infrastructure in order to promote business process reform globally aimed at creating new value and strengthening our corporate capabilities. In addition to improving productivity across the group, we aim to achieve digital transformation (DX) that creates new solutions for customers.」

「We will continue efforts to renew next-generation core systems and digital infrastructure in order to promote business process reform globally aimed at creating new value and strengthening our corporate capabilities. In addition to improving productivity across the group, we aim to achieve digital transformation (DX) that creates new solutions for customers.」

「Going forward, in addition to PCR, antigen, antibody, and cytokine testing, we will contribute to establishing research, diagnosis, and treatment for COVID-19 through a variety of tests, including our existing hematology and blood coagulation tests.」

「We will enhance the applications of Caresphere™, which we have already begun providing, and pursue digital transformation (DX) to transform customer support and create new solutions for customers.」

「We began sales in Japan to medical institutions of the hinotori™ Surgical Robot System, a surgical robot unit developed by Medicaroid Corporation, established through a joint investment by Kawasaki Heavy Industries,Ltd. and our company, and the HF Series Instruments, reusable active endoscopic instruments, also developed by Medicaroid (collectively, hinotori™). As Japan's first domestically developed surgical-assistance robot, hinotori™ lowers barriers to adoption through its compact design and implementation and maintenance plans that support hospital management. Its high usability and network support for monitoring operating status also help healthcare professionals perform procedures with greater precision.」

「In August 2020, we launched the new CN-6500/CN-3500 Fully Automated Blood Coagulation Analyzers for the blood coagulation testing field. The product incorporates a measurement unit using chemiluminescence enzyme immunoassay (CLEIA), enabling measurement of coagulation molecular markers in addition to the blood coagulation and platelet aggregation tests available on the conventional CN-6000/CN-3000 Fully Automated Blood Coagulation Analyzers. As a result, the product can perform a broad range of tests in the thrombosis and hemostasis fields on a single instrument.」

「This integrated system retains the high productivity, reliability, usability, and serviceability of our CN-6000/CN-3000 Fully Automated Blood Coagulation Analyzers while adding a unit based on chemiluminescence enzyme immunoassay (CLEIA), the measurement principle used in our HISCL™-5000/HISCL™-800 Fully Automated Immunoassay Systems. In addition to the blood coagulation and platelet aggregation tests available on the conventional CN-6000/CN-3000, the system can flexibly perform a broad range of tests in the thrombosis and hemostasis fields, including coagulation molecular markers measured using CLEIA, thereby enabling an efficient testing workflow tailored to the needs of healthcare settings.」

「In September 2019, we launched Caresphere™ QM, an application that supports the operation of clinical laboratories based on ISO 15189, the international standard specifying requirements for the quality and competence of clinical laboratories.」

「In September 2019, we launched Caresphere™ QM, an application that supports the operation of clinical laboratories based on ISO 15189, the international standard specifying requirements for the quality and competence of clinical laboratories.」

「In December 2018, we launched the CN-6000/CN-3000 Fully Automated Blood Coagulation Analyzers in Japan to further improve the efficiency and quality of blood coagulation testing. Compared with previous products, the analyzers reduce testing time and have a more compact design. They can also be linked to our new Caresphere™ network solution, enabling users to monitor and analyze the status of the instruments and the operating status of the laboratory as a whole. We plan to introduce the products to overseas markets going forward.」

「Our group provides total solutions combining specimen testing instruments, specimen testing reagents, IT, and services and support, and strives to respond closely to increasingly diverse needs.」

「We provide total solutions combining specimen testing instruments, specimen testing reagents, IT, and services and support, and strive to respond closely to increasingly diverse needs.」

「The company also embraces the concept of a total solutions provider and is pursuing integrated product development covering not only specimen testing instruments but also specimen testing reagents and clinical laboratory information systems.」